- Home
- GLPG vs NNNN Comparison
GLPG vs NNNN Comparison
Compare GLPG & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- NNNN
- Stock Information
- Founded
- GLPG 1999
- NNNN 2021
- Country
- GLPG Belgium
- NNNN Germany
- Employees
- GLPG N/A
- NNNN N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GLPG Health Care
- NNNN Health Care
- Exchange
- GLPG Nasdaq
- NNNN Nasdaq
- Market Cap
- GLPG 2.1B
- NNNN 2.2B
- IPO Year
- GLPG 2005
- NNNN 2025
- Fundamental
- Price
- GLPG $31.78
- NNNN $16.85
- Analyst Decision
- GLPG Hold
- NNNN
- Analyst Count
- GLPG 4
- NNNN 0
- Target Price
- GLPG $30.00
- NNNN N/A
- AVG Volume (30 Days)
- GLPG 229.6K
- NNNN 38.7K
- Earning Date
- GLPG 11-05-2025
- NNNN 04-28-2026
- Dividend Yield
- GLPG N/A
- NNNN N/A
- EPS Growth
- GLPG N/A
- NNNN N/A
- EPS
- GLPG N/A
- NNNN 0.06
- Revenue
- GLPG $323,674,692.00
- NNNN $8,185,146.00
- Revenue This Year
- GLPG $1.77
- NNNN N/A
- Revenue Next Year
- GLPG $0.44
- NNNN N/A
- P/E Ratio
- GLPG N/A
- NNNN $311.68
- Revenue Growth
- GLPG 5.43
- NNNN 21.95
- 52 Week Low
- GLPG $22.36
- NNNN $5.18
- 52 Week High
- GLPG $37.78
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- GLPG 43.66
- NNNN 26.86
- Support Level
- GLPG $30.92
- NNNN $21.60
- Resistance Level
- GLPG $32.62
- NNNN $24.10
- Average True Range (ATR)
- GLPG 0.84
- NNNN 2.61
- MACD
- GLPG -0.26
- NNNN -0.55
- Stochastic Oscillator
- GLPG 21.08
- NNNN 6.43
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.